Potential Role of Stathmin-2 in Amyotrophic Lateral Sclerosis
Episode 106, Jan 12, 11:00 AM
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Cathleen Lutz, PhD, vice president of the Rare Disease Translational Center at the Jackson Laboratory, provided comment on a recently published study which unveiled that stathmin-2 loss leads to neurofilament-dependent axonal collapse in patients with amyotrophic lateral sclerosis (ALS). Lutz offered insight on the role stathmin-2 may have in this disease, the questions that still remain, and whether restoration of stathmin-2 may be an attractive therapeutic approach. Furthermore, she spoke on the potential of this protein as a disease-modifying biomarker and whether it may be incorporated in trials in the near future.
Looking for more neuromuscular discussion? Check out the NeurologyLive® neuromuscular clinical focus page.
Episode Breakdown:
In this episode, Cathleen Lutz, PhD, vice president of the Rare Disease Translational Center at the Jackson Laboratory, provided comment on a recently published study which unveiled that stathmin-2 loss leads to neurofilament-dependent axonal collapse in patients with amyotrophic lateral sclerosis (ALS). Lutz offered insight on the role stathmin-2 may have in this disease, the questions that still remain, and whether restoration of stathmin-2 may be an attractive therapeutic approach. Furthermore, she spoke on the potential of this protein as a disease-modifying biomarker and whether it may be incorporated in trials in the near future.
Looking for more neuromuscular discussion? Check out the NeurologyLive® neuromuscular clinical focus page.
Episode Breakdown:
- 1:15 – Idea behind studying stathmin-2
- 2:45 – Overviewing study results
- 7:05 – Next steps in extending this research
- 8:40 – Neurology News Minute
- 11:30 – Stathmin-2's connection with neurofilament light
- 12:55 – Potential of stathmin-2 as ALS-specific biomarker
- 14:45 – Future use of stathmin-2 in clinical trials
- 15:30 – Closing thoughts
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
FDA Clears Phase 2 KYSA-7 Study of CAR T-Cell Therapy in Refractory Progressive Multiple Sclerosis
Dyne Reports Positive Phase 1/2 Data for Duchenne Agent DYNE-251
Parkinson Gene Therapy AB-1005 Meets Primary End Point in Phase 1b Trial
VISIONARY-MS Trial Reports CNM-Au8 Improves Vision and Cognition in Multiple Sclerosis
Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.